Related Experiment Video
Updated: Jun 21, 2026
Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer
Koji Oba1, Michiya Kobayashi, Takanori Matsui
1EBM Research Center, Kyoto University Graduate School of Medicine, Yoshidakonoe-cho, Kyoto, Japan. oba@pbh.med.kyoto-u.ac.jp
Background:
In the present study, the effect of immunochemotherapy with lentinan compared with that of chemotherapy alone was evaluated in patients with advanced gastric cancer through individual patient data (IPD) meta-analysis.
Materials And Methods:
Based on a computerized and manual search, all eligible centrally randomized controlled trials (RCT) which compared chemotherapy regimens with or without lentinan administration for advanced gastric cancer patients were included.
Results:
In total, 650 IPD from 5 trials were available. Lentinan significantly prolonged the overall survival (stratified log-rank p=0.011). The overall hazard ratio (HR) was 0.80 (95% confidence interval=0.68-0.95) and there was no heterogeneity between trials. Additionally, lentinan was possibly more effective in patients with lymph-node metastasis than in non-node metastasis patients (P for interaction=0.077).
Conclusion:
The addition of lentinan to standard chemotherapy offers a significant advantage over chemotherapy alone in terms of survival for patients with advanced gastric cancer.